Peanut Hypersensitivity

• EMA approval · 2026-02-12
  EMA Authorised: Palforzia (defatted powder of Arachis hypogaea L., semen (peanuts)) — Stallergenes

  The European Medicines Agency authorised Palforzia for peanut hypersensitivity in the EU. The product is a peanut allergen immunotherapy dev…

• EMA withdrawal · 2022-11-23
  EMA Application withdrawn: Abylqis (arachis hypogaea extract) — DBV Technologies

  The EMA has withdrawn the application for Abylqis (arachis hypogaea extract) by DBV Technologies for peanut hypersensitivity.

• CLINICAL_TRIALS trial_result · 2021-12-16
  Clinical Trial Update: FARE Peanut SLIT and Early Tolerance Induction [Phase 2]

  Phase 2 clinical trial update for FARE Peanut SLIT evaluating early tolerance induction in individuals with peanut hypersensitivity and rela…

• CLINICAL_TRIALS trial_result · 2020-01-22
  Clinical Trial Update: Peanut Oral Immunotherapy in Children [Phase 2]

  Phase 2 clinical trial evaluating peanut oral immunotherapy in children for peanut hypersensitivity has completed with results posted.

• CLINICAL_TRIALS trial_result · 2016-08-26
  Clinical Trial Update: Peanut Epicutaneous Phase II Immunotherapy Clinical Trial [Phase 2]

  Phase II immunotherapy trial exploring peanut epicutaneous immunotherapy for peanut hypersensitivity has completed with posted results.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2015-06-25
  Clinical Trial Update: Oral Peanut Immunotherapy for Peanut Allergic Patients [EARLY_Phase 1]

  An early Phase 1 trial of oral peanut immunotherapy for peanut allergy has completed.

• CLINICAL_TRIALS trial_result · 2012-10-30
  Clinical Trial Update: A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial [Phase 1, Phase 2]

  A randomized, double-blind, placebo-controlled trial evaluating peanut sublingual immunotherapy in phase 1/2 has completed with posted resul…